drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An intravenous antibody–drug conjugate (ADC) dosed every 3 weeks. A monoclonal antibody binds a tumor-associated surface antigen on solid tumors, is internalized, and releases a cytotoxic payload to kill antigen-positive cells. Based on protocol exclusions, it likely targets B7‑H3 (CD276) and may use a topoisomerase I inhibitor payload (not explicitly confirmed).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous ADC in which a monoclonal antibody binds a tumor‑associated surface antigen on solid tumors (protocol suggests B7‑H3/CD276), is internalized, and releases a cytotoxic payload—likely a topoisomerase I inhibitor—to induce DNA damage and kill antigen‑positive tumor cells.
drug_name
7MW3711
nct_id_drug_ref
NCT06008379